$90.97
0.36% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US0234361089
Symbol
AMED

Amedisys, Inc. Stock price

$90.97
-6.25 6.43% 1M
-5.26 5.47% 6M
-4.09 4.30% YTD
-3.12 3.32% 1Y
-67.49 42.59% 3Y
-72.32 44.29% 5Y
+64.87 248.54% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.33 0.36%
ISIN
US0234361089
Symbol
AMED
Sector

Key metrics

Market capitalization $2.98b
Enterprise Value $3.25b
P/E (TTM) P/E ratio 36.22
EV/FCF (TTM) EV/FCF 15.92
EV/Sales (TTM) EV/Sales 1.40
P/S ratio (TTM) P/S ratio 1.28
P/B ratio (TTM) P/B ratio 2.60
Revenue growth (TTM) Revenue growth 4.19%
Revenue (TTM) Revenue $2.32b
EBIT (operating result TTM) EBIT $211.79m
Free Cash Flow (TTM) Free Cash Flow $204.37m
Cash position $245.45m
EPS (TTM) EPS $2.51
P/E forward 29.92
P/S forward 1.27
EV/Sales forward 1.39
Short interest 7.03%
Show more

Is Amedisys, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Amedisys, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Amedisys, Inc. forecast:

8x Hold
100%

Analyst Opinions

8 Analysts have issued a Amedisys, Inc. forecast:

Hold
100%

Financial data from Amedisys, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,321 2,321
4% 4%
100%
- Direct Costs 1,717 1,717
24% 24%
74%
604 604
28% 28%
26%
- Selling and Administrative Expenses 367 367
43% 43%
16%
- Research and Development Expense - -
-
-
237 237
20% 20%
10%
- Depreciation and Amortization 25 25
9% 9%
1%
EBIT (Operating Income) EBIT 212 212
22% 22%
9%
Net Profit 83 83
3,029% 3,029%
4%

In millions USD.

Don't miss a Thing! We will send you all news about Amedisys, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amedisys, Inc. Stock News

Negative
Reuters
14 days ago
The Justice Department and three U.S. states filed a lawsuit on Tuesday to block UnitedHealth Group's $3.3 billion purchase of Amedisys Inc over concern the deal would harm competition in the market for home health services, the department said.
Negative
Reuters
14 days ago
The U.S. Justice Department is moving to block UnitedHealth Group's $3.3 billion purchase of Amedisys Inc. over concerns the deal would harm competition in the market for home health services, Bloomberg News reported on Tuesday, citing people familiar with the matter.
Neutral
GlobeNewsWire
20 days ago
BATON ROUGE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2024.
More Amedisys, Inc. News

Company Profile

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.

Head office United States
CEO Richard Ashworth
Employees 19,000
Founded 1982
Website www.amedisys.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today